Heart Disease Trial, Recruiting NCT06887413 Sponsor: Ceric Sàrl Condition: Heart Disease
Back to Heart Disease

Heart Disease Trial, Recruiting

NCT06887413
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 19 and 74 years old
  • People experiencing a specific type of heart attack (called an anterior STEMI) showing significant changes on a heart tracing (ECG) in the front-wall leads, with abnormal heart wall movement confirmed by imaging
  • People where the blockage causing the heart attack is located in the upper or middle part of a specific heart artery (the LAD artery), as seen on imaging
  • People where the blocked artery has a large blood clot or no blood flow even after a guidewire is passed through it
  • People who arrive at the hospital between 1 and 6 hours after their chest pain started
  • People for whom doctors have decided a procedure to open the blocked artery (called primary PCI) is the right treatment

Who may not be able to join:

  • People who are unable to give their own informed consent
  • People whose life expectancy is less than 1 year
  • People for whom the artery-opening procedure (PCI) is medically not suitable
  • People whose heart attack was caused by a previously placed stent becoming blocked
  • People whose blocked artery was caused by a spontaneous tear in the artery wall
  • People who had any procedure to restore blood flow before being enrolled in the trial
  • People who had a cardiac arrest that was not witnessed, or who needed CPR for 30 minutes or more, or who had any cardiac arrest that resulted in confusion, memory problems, or any brain or nerve-related symptoms
  • People showing new stroke symptoms before the procedure, with a stroke severity score above 2 (confirm with trial site)
  • People with a known allergy or intolerance to aspirin, clopidogrel, ticagrelor, heparin, or contrast dye used in imaging
  • People with active serious bleeding
  • People with severe liver or kidney disease
  • People who received clot-dissolving medication within the 24 hours before enrolment
  • People in cardiogenic shock — a serious condition where blood pressure is very low and the body's organs are not getting enough blood — along with additional signs of organ failure or need for mechanical heart support
  • People whose heart attack involves the lower wall of the heart, or where the right side of the heart is suspected to be failing
  • People with severe disease of the heart valves
  • People experiencing a serious mechanical complication of the heart, such as a rupture of the heart wall, a hole between the heart's chambers, or sudden severe leaking of the heart's mitral valve
  • People who are pregnant or possibly pregnant
  • People with a suspected active infection throughout the body
  • People with known liver insufficiency before the procedure
  • People currently receiving dialysis or another form of kidney replacement therapy
  • People with severe chronic lung disease (COPD) who use home oxygen or take ongoing steroid medication
  • People who cannot have an MRI scan or receive MRI contrast dye — for example, due to kidney function below a certain level, an incompatible implanted device, or claustrophobia
  • People with evidence of a previous heart attack, including certain abnormal patterns on their ECG in specific leads
  • People who have previously had open-heart bypass surgery or a procedure to open the LAD artery
  • People with a history of heart failure, including a documented weak heart pump (ejection fraction below 40%) or a hospital admission for heart failure within the past year
  • People who have previously had aortic valve surgery or a transcatheter aortic valve replacement (TAVR)
  • People with a specific electrical conduction problem in the heart called left bundle branch block (whether new or pre-existing)
  • People who have had a stroke or mini-stroke (TIA) within the 3 months before screening

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Alaide Chieffo, San Raffaele Hospital

Phone: +33 (0)1 60 11 17 91

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ceric Sàrl
Registry
ClinicalTrials.gov
Start date
18 February 2026
Est. completion
28 February 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

Microvascular obstruction

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov